- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01295840
Quartet Lead and Resynchronization Therapy Options (QUARTO)
QUARTET LEAD AND RESYNCHRONIZATION THERAPY OPTIONS To Investigate the Stimulatory Possibilities Offered by the Different Configurations Available for the Quartet Lead and Their Effect on Haemodynamic and Clinical Response.
The purpose of this Clinical Trial is to determine the percentage of patients whose hemodynamic response improves with the different configurations offered by the new Quartet® left ventricular lead, as a result of its four electrodes, with respect to the configurations offered by a standard bipolar lead.
Furthermore, the optimal stimulation configuration will be determined from a comparison with traditional configurations.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, non-randomised, multi-centre, national, interventional clinical trial of a medical device.
This trial involves two visits: one at the beginning of the study, which will be undertaken in the seven days following implant, and another visit at 6 months after enrollment. It is recommended that the enrollment visit is undertaken as soon as possible after implantation, although the time window allows the timing to be adapted to each centre's standard practice. Resynchronization therapy in those patients suitable for participation in this trial is expected to begin once this enrollment visit has been completed.
Once data collection at enrollment visit has been completed, final device programming will be based on each investigator's criteria and will be undertaken following the standard practice of each centre.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Málaga, Spain, 29010
- Hospital Clinico Universitario Virgen de la Victoria
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a Cardiac resynchronization Therapy Defibrillator device (CRT-D) and a Quartet® quadripolar electrode from St Jude Medical (used in "Single Site Pacing" mode) implanted in the left ventricle.
- Patients who have provided written informed consent
- Patients who are in sinus rhythm.
- Patients older than 18 years of age.
Exclusion Criteria:
- Patients in atrial fibrillation at the time of the echocardiographic study of the enrollment visit.
- Patients with valvular disease.
- Patients in functional class New York Heart Association (NYHA) IV
- Patients for whom echocardiography images suitable for determining the cardiac output cannot be obtained.
- Patients whose device has been changed/upgraded.
- Pregnant patients.
- Patients who do not fulfill all the inclusion criteria.
- Patients who are unable to provide written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
NO_INTERVENTION: CRT therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
|
Cardiac Resynchronization Therapy Defibrillator
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Patients Whose Cardiac Output (CO) Value in Acute, as Measured Echocardiographically, Improves With the Different Stimulation Vectors Offered by the Quartet® Left Ventricular Electrode.
Time Frame: Enrollment visit (in the seven days after implantation of the device)
|
Enrollment visit (in the seven days after implantation of the device)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Difference Between the Best CO From Non-traditional Vectors and Best CO From Traditional Vectors
Time Frame: At enrollment
|
In patients with best CO obtained from Non-traditional, to calculate the percent difference between the best CO from Non-traditional vectors and best CO from Traditional vectors, vectors.This percentage was the CO from Non-traditional vectors minus CO from Traditional vectors then divided by CO from Traditional vectors. The Quartet® lead has 4 poles: Distal (D1), Mid 2 (M2), Mid 3 (M3) and Proximal (P4). The 3 Traditional vectors are the traditional configurations available in a standard bipolar lead: D1-M2, D1-Right Ventricular Coil (RVC) and M2-RVC. The 7 Non-traditional vectors are the additional configurations available in a Quartet® lead: D1-P4, M2-P4, M3-M2, M3-RVC, M3-P4, P4-M2 and P4-RVC. |
At enrollment
|
|
Cardiac Output (CO) With Different Configurations at Enrollment
Time Frame: Enrollment visit (in the seven days after implantation of the device)
|
Means of baseline non-paced CO, best CO obtained from traditional configurations and best CO obtained from all quadripolar configurations at enrollment.
|
Enrollment visit (in the seven days after implantation of the device)
|
|
Capture Threshold
Time Frame: Enrollment visit (in the seven days after implantation of the device)
|
Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied. Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, whilst maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode. |
Enrollment visit (in the seven days after implantation of the device)
|
|
Capture Threshold
Time Frame: 6 months post-implant
|
Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied. Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, whilst maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode. |
6 months post-implant
|
|
Number of Vectors With Phrenic Nerve Stimulation (PNS)
Time Frame: Enrollment visit (in the seven days after implantation of the device)
|
Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied. Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, while maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode. |
Enrollment visit (in the seven days after implantation of the device)
|
|
Number of Vectors With Phrenic Nerve Stimulation (PNS)
Time Frame: At 6 months
|
Capture and phrenic threshold data will be recorded for each of the stimulation vectors studied. Attempts will also be made to avoid phrenic stimulation in those patients who suffer from it, whilst maintaining good capture thresholds, by changing between the new configurations offered by the Quartet® electrode. |
At 6 months
|
|
Number of Patients With PNS in All Vectors
Time Frame: At enrollment
|
To calculate the number of patients that exhibit PNS in all traditional vector
|
At enrollment
|
|
Number of Patients With PNS in All Vectors, That Could be Avoided With a Non-traditional Vector
Time Frame: At enrollment
|
To calculate the number of patients, who exhibit PNS in all traditional vector, in which PNS could be avoided using a non-traditional vector
|
At enrollment
|
|
Number of Patients With PNS in All Vectors
Time Frame: At 6 months
|
To calculate the number of patients that exhibit PNS in all traditional vector
|
At 6 months
|
|
Number of Patients With PNS in All Vectors, That Could be Avoided With a Non-traditional Vector
Time Frame: At 6 months
|
To calculate the number of patients, who exhibit PNS in all traditional vector, in which PNS could be avoided using a non-traditional vector
|
At 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr. Francisco Javier Alzueta Rodríguez, PhD, Hospital Clinico Universitario Virgen de la Victoria
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR 10-046-SP-HF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
University of Health Sciences LahoreRecruitingAcute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, SystolicPakistan
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Lakeland Regional Health Systems, Inc.RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IVUnited States
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Eli Lilly and CompanyNot yet recruitingHeart Failure | Heart Failure, Diastolic | Heart Failure, SystolicUnited States, Japan
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
Clinical Trials on Cardiac Resynchronization Therapy Defibrillator
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart Failure
-
Boston Scientific CorporationTerminatedHeart FailureBelgium, United States
-
Medtronic Cardiac Rhythm and Heart FailureCompletedCongestive Heart Failure, Atrial Arrhythmia, Atrial Tachyarrhythmia, Atrial FibrillationGermany, Italy, United States, Spain, Denmark, Netherlands, Norway, Switzerland, Japan, Austria, Greece, United Kingdom
-
Boston Scientific CorporationCompletedCongestive Heart FailureUnited States
-
Boston Scientific CorporationUniversity of RochesterCompletedTachycardia | Congestive Heart FailureUnited States
-
Abbott Medical DevicesCompleted
-
LivaNovaCompleted
-
Pusan National University HospitalNot yet recruitingCardiac Implantable Electronic Device | Atrial High Rate EpisodeKorea, Republic of
-
University of RochesterCompletedSystolic Heart Failure | Atrial Fibrillation (Permanent)United States